Advertisement

Rapid Generation of Dityrosine Cross-linked Aβ Oligomers via Cu-Redox Cycling

  • Adam P. Gunn
  • Blaine R. Roberts
  • Ashley I. BushEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 849)

Abstract

There is a great interest in the role of free radicals and oxidative stress in Alzheimer’s disease and for the role of transition metals in the generation of oligomers of Aβ peptides. In the literature, there are a multitude of varying methods that can be used to create soluble oligomers of Aβ, however, the processes that create these oligomers are often stochastic by nature and thus reproducibility is an issue. Here we report a simple and reproducible method for the production of radically derived dityrosine cross-linked oligomers of Aβ, through reaction with copper and ascorbic acid.

Key words

Amyloid beta Aβ Alzheimer’s disease Dityrosine Hydroxyl radical Copper 

Notes

Acknowledgments

This work was supported by the Mental Health Research Institute (Parkville, VIC, Australia) and the Centre for Neuroscience, University of Melbourne (Parkville, VIC, Australia).

References

  1. 1.
    Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G and P.R. Carey (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence, Biochemistry 42, 2768–2773.PubMedCrossRefGoogle Scholar
  2. 2.
    Lue L-F, Kuo Y-M, Roher AE, et al. (1999) Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 155, 853–862.PubMedCrossRefGoogle Scholar
  3. 3.
    Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer’s disease from normal and pathologic aging. Experimental Neurology 158, 328–337.PubMedCrossRefGoogle Scholar
  4. 4.
    McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, et al. (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 46, 860–866.PubMedCrossRefGoogle Scholar
  5. 5.
    Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, et al. (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease. Acta Neuropathol. Google Scholar
  6. 6.
    Guntert A, Dobeli H, Bohrmann B (2006) High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143, 461–475.PubMedCrossRefGoogle Scholar
  7. 7.
    Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, et al. (1993) Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J Biol Chem 268, 3072–3083.PubMedGoogle Scholar
  8. 8.
    Kaneko I, Morimoto K, Kubo T (2001) Drastic neuronal loss in vivo by β-amyloid racemized at Ser(26) residue: conversion of non-toxic (D-Ser(26))β-amyloid 1–40 to toxic and proteinase-resistant fragments. Neuroscience 104, 1003–1011.PubMedCrossRefGoogle Scholar
  9. 9.
    Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, et al. (1995) Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 14, 457–466.PubMedCrossRefGoogle Scholar
  10. 10.
    Piccini A, Russo C, Gliozzi A, Relini A, Vitali A, et al. (2005) Beta amyloid is different in normal aging and in Alzheimer disease. J Biol Chem 280, 34186–34192.PubMedCrossRefGoogle Scholar
  11. 11.
    Head E, Garzon-Rodriguez W, Johnson JK, Lott IT, Cotman CW, et al. (2001) Oxidation of Aβ and plaque biogenesis in Alzheimer’s disease and Down syndrome. Neurobiol Dis 8, 792–806.PubMedCrossRefGoogle Scholar
  12. 12.
    Butterfield DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer’s disease brain: new insights from redox proteomics. Eur J Pharmacol 545, 39–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer’s disease based on the metal hypothesis. Neurotherapeutics 5, 421–432.PubMedCrossRefGoogle Scholar
  14. 14.
    Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropath. Exp. Neurology 60, 759–767.Google Scholar
  15. 15.
    Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21, 4183–4187.PubMedGoogle Scholar
  16. 16.
    Duce JA, Bush AI (2010) Biological metals and Alzheimer’s disease: implications for therapeutics and diagnostics. Prog Neurobiol 92, 1–18.PubMedCrossRefGoogle Scholar
  17. 17.
    Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, et al. (1998) Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273, 12817–12826.PubMedCrossRefGoogle Scholar
  18. 18.
    Schapira AH (1996) Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr Opin Neurol 9, 260–264.PubMedCrossRefGoogle Scholar
  19. 19.
    Sparks DL (1997) Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer’s disease? Ann N Y Acad Sci 826, 128–146.PubMedCrossRefGoogle Scholar
  20. 20.
    Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, et al. (2000) Characterization of copper interactions with Alzheimer amyloid β peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75, 1219–1233.PubMedCrossRefGoogle Scholar
  21. 21.
    Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, et al. (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer’s disease β-amyloid. FASEB J 18, 1427–1429.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Adam P. Gunn
    • 1
  • Blaine R. Roberts
    • 1
  • Ashley I. Bush
    • 1
    Email author
  1. 1.Mental Health Research InstituteUniversity of MelbourneParkvilleAustralia

Personalised recommendations